Your Daily Biotechnology Briefing

FDA Greenlights New Therapies as Rapid Diagnostics Advance

• The Food and Drug Administration (FDA) has cleared brepocitinib, to be sold as Lisraya, as the first oral therapy for dermatomyositis, a rare skin condition causing muscle weakness and lesions. Licensed by Priovant Therapeutics from Pfizer, a 30-day supply of Lisraya will have a list price of $35,000.

  Biopharmadive

• Takeda received U.S. FDA approval for MIMRYLO™ (rusfertide) on August 28, 2026, marking a potential shift in the treatment paradigm for erythrocytosis in adults with polycythemia vera, a blood cancer. MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution and red blood cell overproduction.

  Businesswire

• A new diagnostic platform called STREAM (sedimentation-assisted tandem rocking and enrichment for analysis and monitoring) could cut sepsis diagnosis time from days to as little as 6.75 hours. Developed by researchers from Stanford University and Penn State University with NIH funding, this platform addresses the challenge of detecting scarce bacteria in bloodstream infections.

  Globalbiodefense